News & Analysis

Curated news and analysis on clinical trials, drug approvals, and medical research.

Myeloma Immunotherapies Show Promise, but Access Barriers Persist

Multiple myeloma immunotherapies like bispecific antibodies and CAR-T cells show high response rates and prolonged survival, but access is hindered by the need for initial hospital stays for bispecifics. Research indicates mezigdomide can reverse T cell exhaustion to boost these therapies, while longer-term CARVYKTI data show significant survival benefits.

Institutional Investors Report Mixed AstraZeneca Holdings Changes in Recent Filings

Groupama Asset Management acquired a new stake in AstraZeneca, while ING Groep NV trimmed its position, reflecting mixed institutional activity. Amundi, Janus Henderson, and Royal Bank of Canada significantly increased their holdings in the first quarter. Institutional investors and hedge funds own 20.35% of AstraZeneca's stock.

US Launches New Strikes on Iran as Conflict Escalates, Tehran Warns of Wider War

The US launched fresh strikes on Iran's coastal defenses and missile sites, escalating the conflict over control of the Strait of Hormuz. Iran retaliated against US regional bases and warned of wider energy shutdowns, while a major US naval and air buildup signals potential sustained military action. The war has killed thousands and raised global energy fears.

Cancer Survival Rate Reaches Historic 70% in ACS 2026 Report

The American Cancer Society's 2026 statistics show a historic 70% 5-year relative survival rate for all cancers, up from 49% in the mid-1970s. Progress is attributed to earlier detection, targeted therapies, and immunotherapies, though disparities persist for American Indian and Alaska Native populations.

Greener Production Methods Emerge for Weight-Loss Drugs

Pharmaceutical manufacturers are shifting to greener production methods for GLP-1 peptide weight-loss drugs like Ozempic and Wegovy, reducing reagent waste and moving away from restricted solvents. The traditional process uses up to 13,000 kg of reagents per kg of peptide. Expert Fernando Albericio also calls for ethical use of these medications, often dubbed 'Hollywood drugs.'

Senate Committee Advances Bill to Streamline Biosimilar Approvals

The Senate HELP Committee advanced a bill to streamline biosimilar approvals by relying on analytical tests, potentially cutting development costs and time. The FDA has issued guidance removing comparative efficacy studies and is working to speed post-exclusivity approvals. Combined with administration support and PBM reforms, these moves aim to increase biosimilar competition and reduce drug prices.

Newer
Sorted by date
Older
Showing 20 articles per page